丹纳赫集团与正序生物合作开发基因编辑创新疗法工艺平台 为基因遗传疾病的治疗提供新途径

新浪医药
Jul 15, 2025

此次Danaher Beacon项目致力于开发基于脂质纳米颗粒递送的基因编辑创新疗法全流程工艺技术平台该项目将探索脂质纳米颗粒作为基因编辑递送系统在遗传性疾病治疗中的应用潜力2025年7月14日,全球科学与技术的创新者丹纳赫宣布其旗下运营公司Cytiva思拓凡与正序生物开展战略合作,共同开发基于脂质纳米颗粒递送系统的基因治疗创新工艺解决方案,以推动基因编辑技术在遗传性疾病治疗领域的突破。这也是...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10